The etiological link between hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) has been suggested on epidemiologic, serologic and molecular grounds. This link has, however, recently been questioned by prospective studies suggesting that HBV infection also causes cirrhosis and that whatever the cause of cirrhosis, the risk of developing HCC could be roughly similar. All male patients first admitted to Hôpital Beaujon with cirrhosis or HCC from 1983 to 1987 were included in a cross-sectional study. A total of 277 new patients with cirrhosis (but free of HCC) were admitted, of whom 55 were HBsAg positive, and 181 were alcoholic. During the same period, 117 new patients with HCC were admitted, 48 in association with alcoholic cirrhosis, 36 with HBsAg positive cirrhosis. The relative risk (odds ratio) of HCC was 2.5 (95% confidence interval, 1.46-4.37; p = 0.0011) in patients with HBsAg positive cirrhosis as compared to patients with alcoholic cirrhosis. HBsAg positive patients were significantly younger than their alcoholic counterparts (48 +/- 14 vs 54 +/- 10 years in the cirrhotic group; 49 +/- 12 vs 62 +/- 8 years in the HCC group). We conclude that, using the methodology of a cross-sectional study, the relative risk of HCC was about twice greater in HBV-associated than alcoholic cirrhosis. The results of longitudinal prospective studies examining this issue might be biased by selecting patients older than the mean age of HCC occurrence or excluding patients with HCC when present at first admission.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0676.1990.tb00450.x | DOI Listing |
Niger Med J
January 2025
Department of Obstetrics and Gynaecology, Federal University of Health Sciences, Azare, Bauchi State, Nigeria.
Background: Infection with the human immunodeficiency virus and hepatitis viruses B and C have been reported to be endemic in some Nigeria's institutions of higher learning. Several studies have reported varying prevalence rates for hepatitis B and C viruses and HIV among undergraduate students in Nigerian universities.
Methodology: A cross-sectional descriptive prevalence study of hepatitis B and C viruses and HIV among students at Federal University of Health Sciences, Azare conducted on the 2nd of December 2023.
IJID Reg
March 2025
Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Objectives: The chemiluminescence immunoassay automated Abbott ARCHITECT hepatitis B surface antigen (HBsAg) screening assay is globally recognized for its superior sensitivity but notably low specificity. This mandates positive results confirmation by another confirmatory assay, such as the widely used Abbott ARCHITECT HBsAg neutralizing assay. This study aimed to evaluate the performance of the new chemiluminescence immunoassay, Mindray CL-900i HBsAg screening assay in comparison to the ARCHITECT neutralizing/confirmatory assay.
View Article and Find Full Text PDFWorld J Hepatol
January 2025
Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Hepatitis B virus (HBV) infection is a global health concern. The current sequential endpoints for the treatment of HBV infection include viral suppression, hepatitis B e antigen (HBeAg) seroconversion, functional cure, and covalently closed circular DNA (cccDNA) clearance. Serum hepatitis B core-related antigen (HBcrAg) is an emerging HBV marker comprising three components: HBeAg, hepatitis B core antigen, and p22cr.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin, China.
Objective: Although pegylated interferon α-2b (PEG-IFN α-2b) therapy for chronic hepatitis B has received increasing attention, determining the optimal treatment course remains challenging. This research aimed to develop an efficient model for predicting interferon (IFN) treatment course.
Methods: Patients with chronic hepatitis B, undergoing PEG-IFN α-2b monotherapy or combined with NAs (Nucleoside Analogs), were recruited from January 2018 to December 2023 at Tianjin Third Central Hospital.
Background: Uzbekistan, a highly endemic country for hepatitis B virus (HBV), introduced infant vaccination with hepatitis B vaccine (HepB) in 2001. Since 2002, it had ≥90 % reported immunization coverage for ≥3 doses of HepB (HepB3) and the birth dose (HepB-BD). However, the impact of HepB vaccination and the progress towards achieving the regional hepatitis B control and global viral hepatitis B elimination goals had not been assessed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!